New research from the CWMH.
Data from an ongoing pregnancy registry offers reassurance that benzodiazepines do not appear to have major teratogenic effects.
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.
Based on this large cohort study including 990 pregnancies with first trimester exposure to atomoxetine, the researchers observed no increase in major congenital malformations overall and no statistically increased risk estimates for cardiac or limb malformations.
TMS in pregnancy and the postpartum period appears to be a promising treatment option with no reports of adverse obstetric outcomes or congenital malformations.
Although the last decade has brought increased awareness of and interest in postpartum mood and anxiety disorders, our understanding of the etiology of this most severe form of postpartum mental illness remains elusive.
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
It's World Menopause Day. October 18th was designated by the International Menopause Society (IMS) to raise awareness of the menopause and to support options to improve health and well-being for [...]
A recent review and meta-analysis found that upwards of 20% of women with no history of psychiatric illness experience their first bipolar-spectrum mood episode during the perinatal period.
A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
